We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Finger Prick Test Could Predict COVID-19 Complications from Drop of Blood

By LabMedica International staff writers
Posted on 12 Sep 2022
Print article
Image: New technology is being designed to detect severe COVID complications such as thrombosis (Photo courtesy of Pexels)
Image: New technology is being designed to detect severe COVID complications such as thrombosis (Photo courtesy of Pexels)

Many people died from COVID-19 because of the rapid development of complications caused by the so-called immune system-induced cytokine storm during which the body releases too many inflammatory proteins called cytokines into the blood too quickly. Symptoms include high fever, severe fatigue and sometimes organ failure. A cytokine storm can lead to abnormal blood clotting through the body’s blood vessels. For COVID-19 patients, it can lead to complications that contribute to respiratory difficulties and ultimately cause the patient’s death. But could some of those who died from COVID-19 and other infectious diseases have been saved by a diagnosis that predicts how severe their cases will be and provides timelier treatment?

An interdisciplinary team of engineers and doctors at Tulane University (New Orleans, LA, USA) hopes to answer that question with the development of new technology designed to detect severe COVID complications such as thrombosis, a condition in which blood clots block veins and arteries. The team has received a nearly USD 600,000 Trailblazer Award from the National Institute of Biomedical Imaging and Bioengineering to take on research that will lead to tests that can predict the severity of infectious diseases. The goal is to develop a diagnostic test that uses a drop of blood from a finger prick – a test that could be performed at a hospital, in a clinic or at home.

“Many patients who died from COVID-19 and other infectious diseases developed severe thrombotic complications shortly after disease symptoms were manifested,” said Damir Khismatullin, PhD, an associate professor of biomedical engineering in the Tulane School of Science and Engineering. “Their lives could be saved by predictive diagnosis of disease severity and timely treatment. However, tests that effectively predict the severity of infectious diseases are not available yet.”

Related Links:
Tulane University

Gold Member
COVID-19 TEST READER
COVID-19-CHECK-1 EASY READER+
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Benchtop Cooler
PCR-Cooler & PCR-Rack
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.